Publications by authors named "Natale Imbesi"
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Pierpaolo Correale Rita Emilena Saladino Diana Giannarelli Rocco Giannicola Rita Agostino Natale Imbesi
J Immunother Cancer
June 2020
Article Synopsis
- - Nivolumab is a targeted cancer therapy for metastatic non-small cell lung cancer (mNSCLC) that helps restore the function of T cells but can lead to immune-related side effects and has no clear predictive biomarkers for treatment success.
- - A study analyzed 119 mNSCLC patients treated with nivolumab to examine the effects of specific HLA genetic variations on treatment outcomes and side effect frequency.
- - Results showed that the presence of certain HLA-A alleles (like HLA-A*01) correlated with better patient survival rates, suggesting that HLA genotyping could help predict treatment efficacy and inform future cancer immunotherapy research.